NO961006L - Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene - Google Patents

Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene

Info

Publication number
NO961006L
NO961006L NO961006A NO961006A NO961006L NO 961006 L NO961006 L NO 961006L NO 961006 A NO961006 A NO 961006A NO 961006 A NO961006 A NO 961006A NO 961006 L NO961006 L NO 961006L
Authority
NO
Norway
Prior art keywords
phosphonomononucleic
acids
compounds
processes
preparation
Prior art date
Application number
NO961006A
Other languages
English (en)
Other versions
NO961006D0 (no
NO328646B1 (no
Inventor
Anuschirwan Peyman
Eugen Uhlmann
Gerhard Breipohl
Holger Wallmeier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19508923A external-priority patent/DE19508923A1/de
Priority claimed from DE1995143865 external-priority patent/DE19543865A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO961006D0 publication Critical patent/NO961006D0/no
Publication of NO961006L publication Critical patent/NO961006L/no
Publication of NO328646B1 publication Critical patent/NO328646B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4087—Esters with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19961006A 1995-03-13 1996-03-12 Fosfonomononukleinsyrer, anvendelse samt fremgangsmater for fremstilling NO328646B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19508923A DE19508923A1 (de) 1995-03-13 1995-03-13 Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE1995143865 DE19543865A1 (de) 1995-11-24 1995-11-24 Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (3)

Publication Number Publication Date
NO961006D0 NO961006D0 (no) 1996-03-12
NO961006L true NO961006L (no) 1996-09-16
NO328646B1 NO328646B1 (no) 2010-04-19

Family

ID=26013308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961006A NO328646B1 (no) 1995-03-13 1996-03-12 Fosfonomononukleinsyrer, anvendelse samt fremgangsmater for fremstilling

Country Status (21)

Country Link
US (2) US5874553A (no)
EP (1) EP0739898B1 (no)
JP (1) JP3917680B2 (no)
KR (1) KR100434213B1 (no)
CN (1) CN1060781C (no)
AR (1) AR002714A1 (no)
AT (1) ATE206131T1 (no)
AU (1) AU706470B2 (no)
BR (1) BR9600993B1 (no)
CA (1) CA2171589C (no)
CZ (1) CZ292037B6 (no)
DE (1) DE59607750D1 (no)
DK (1) DK0739898T3 (no)
ES (1) ES2165446T3 (no)
HU (1) HUP9600647A3 (no)
IL (1) IL117423A (no)
NO (1) NO328646B1 (no)
NZ (1) NZ286150A (no)
PL (1) PL184920B1 (no)
PT (1) PT739898E (no)
UA (1) UA44253C2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO1998035753A1 (de) * 1997-02-17 1998-08-20 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Vorrichtung für eine automatisierte chemische synthese
WO1998051697A2 (de) * 1997-05-14 1998-11-19 Morphochem Ag Verfahren zur herstellung von polymeren, die nucleobasen als seitengruppen aufweisen
DE19741738A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Linker-Nucleosid, seine Herstellung und Verwendung
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
GB9929487D0 (en) * 1999-12-15 2000-02-09 Zeneca Ltd Antisense oligonucleotides
AU2001247414A1 (en) 2000-03-14 2001-09-24 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US20040014644A1 (en) * 2000-03-14 2004-01-22 Vladimir Efimov Oligonucleotide analogues and methods of use for modulating gene expression
DE10019135A1 (de) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
DE10019136A1 (de) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
WO2004043979A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7276599B2 (en) * 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
US20060241072A1 (en) * 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
CA2569036A1 (en) * 2004-06-03 2005-12-22 Balkrishen Bhat Chimeric gapped oligomeric compositions
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20060281100A1 (en) * 2005-06-14 2006-12-14 Shen Gene G Thiotriphosphate nucleotide dye terminators
UA107784C2 (en) * 2008-12-22 2015-02-25 Pola Chem Ind Inc Inhibitor of melanin production
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP4061959A4 (en) * 2019-11-20 2024-01-03 Universal Sequencing Technology Corporation MODIFIED DNA FOR MOLECULAR ELECTRONICS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4374847A (en) * 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
US5264562A (en) * 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DE4016596A1 (de) * 1990-05-23 1991-11-28 Hoechst Ag Ein neues kupplungsreagenz fuer die peptidsynthese
IL104461A (en) * 1992-01-22 2001-05-20 Hoechst Ag Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
WO1994022864A1 (en) * 1993-03-30 1994-10-13 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
CA2159629A1 (en) * 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
WO1994022868A1 (en) * 1993-04-01 1994-10-13 University Of Virginia 7-azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
CN1138588A (zh) 1996-12-25
JPH08259579A (ja) 1996-10-08
NZ286150A (en) 1998-07-28
NO961006D0 (no) 1996-03-12
UA44253C2 (uk) 2002-02-15
US5874553A (en) 1999-02-23
CN1060781C (zh) 2001-01-17
AR002714A1 (es) 1998-04-29
BR9600993A (pt) 1997-12-30
DE59607750D1 (de) 2001-10-31
AU4802896A (en) 1996-09-26
ATE206131T1 (de) 2001-10-15
HUP9600647A3 (en) 1998-04-28
PT739898E (pt) 2002-03-28
IL117423A (en) 2006-08-20
AU706470B2 (en) 1999-06-17
BR9600993B1 (pt) 2010-05-18
CA2171589C (en) 2011-05-10
HU9600647D0 (en) 1996-05-28
NO328646B1 (no) 2010-04-19
HK1012398A1 (en) 1999-07-30
IL117423A0 (en) 1996-07-23
CA2171589A1 (en) 1996-09-14
PL313207A1 (en) 1996-09-16
KR100434213B1 (ko) 2004-09-10
EP0739898A3 (de) 1998-09-16
CZ74396A3 (en) 1996-10-16
ES2165446T3 (es) 2002-03-16
EP0739898A2 (de) 1996-10-30
CZ292037B6 (cs) 2003-07-16
JP3917680B2 (ja) 2007-05-23
HUP9600647A1 (en) 1997-05-28
PL184920B1 (pl) 2003-01-31
EP0739898B1 (de) 2001-09-26
KR960034213A (ko) 1996-10-22
US6127346A (en) 2000-10-03
DK0739898T3 (da) 2001-12-10

Similar Documents

Publication Publication Date Title
NO961006D0 (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
NO305833B1 (no) Naftylforbindelser, mellomprodukter og anvendelse av forbindelsene
FI973281L (fi) Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO981800L (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
DE69513671D1 (de) Arzneimittel
NO944871D0 (no) Fremgangsmåte for fremstilling av polydimetylsiloksaner
FI971268A7 (fi) Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
NO982237L (no) FremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO955082L (no) Fremgangsmåte for fremstilling av glutardialdehyd
FI971267L (fi) Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
NO996432D0 (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
NO307080B1 (no) Fremgangsmåte for fremstilling av katalysatorer og anvendelse derav
FI964410A7 (fi) Menetelmä 4-amino-delta4-3-ketosteroidien valmistamiseksi 4-nitro-delt a4-3-ketosteroidien kautta
NO971419L (no) Fremgangsmåte for fremstilling av 1,3-alkendioler og 3-hydroksyaldehyder
FI940551A0 (fi) Menetelmä fenyylibentsamidijohdannaisten valmistamiseksi
FI953617L (fi) Menetelmä substituoitujen 4-hydroksikumariinien valmistamiseksi
NO20003077L (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO972129D0 (no) Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater
FI951441A7 (fi) Menetelmä 5-formyyliamino-pyrimidiinien valmistamiseksi
NO20002476L (no) FremgangsmÕte for fremstilling av formylimidazoler
NO964519D0 (no) Fremgangsmåte for fremstilling av chitosanalkylderivater
FI970039A7 (fi) Menetelmä 5-aryyli-2,4-dialkyyli-3H-1,2,3-triatsoli-3-tionien valmista miseksi

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees